Inhibikase Therapeutics, Inc. (IKT) Financials

IKT Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 173.3 million 5.7 million
Dec. 31, 2025 181.2 million 8.3 million
Sept. 30, 2025 79.6 million 6.7 million
June 30, 2025 88.9 million 8.8 million

IKT Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -12.1 million 5.6 million
Dec. 31, 2025 -8.0 million 4.5 million
Sept. 30, 2025 -10.6 million 4.5 million
June 30, 2025 -5.6 million 4.2 million

IKT Net Income

No data available :(

IKT Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 170.4 million - -
Dec. 31, 2025 178.8 million - -
Sept. 30, 2025 77.3 million - -
June 30, 2025 87.7 million - 37944

IKT Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 1.7 million
Dec. 31, 2025 98.3 million
Sept. 30, 2025 90.1 million
June 30, 2025 90.0 million

IKT Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 10.8 million 7.4 million -
Dec. 31, 2025 452023 6.4 million 6.8 million -
Sept. 30, 2025 452023 7.6 million 5.6 million -
June 30, 2025 - 5.3 million 5.9 million -

IKT Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - -
Dec. 31, 2025 - 36811
Sept. 30, 2025 - 23688
June 30, 2025 - 24157

IKT

Price: $1.67

52 week price:
1.33
2.26

Earnings Per Share: -0.44 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 146895

Market Capitalization: 224.5 million

Links: